Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

Why big pharma needs to be braver

The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...

Page & Page Health

EU flag

EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine

The vaccine is currently the only inactivated, whole virus adjuvanted candidate in clinical trials in Europe

- PMLiVE

UICC launches global ATOM Coalition to increase access to essential cancer medicines

If left unmonitored, deaths from cancer in poorer countries could rise to four million by 2040

Innovative Medical Solutions for Postponing and Undoing Age-Related Disease

Aubrey de Grey, Chief Science Officer at SENS Research Foundation, discusses a range of interesting topics surrounding innovative interventions and technologies that could not just postpone, but theoretically reverse, age-related...

Impetus Digital

- PMLiVE

Almirall and Evotec team up in multi-target dermatology alliance

The companies will focus on developing novel therapies for chronic skin diseases and skin cancer

- PMLiVE

Moderna wins Prix Galien UK Award for best biotechnology product

The Prix Galien Awards ceremony was held at the National History Museum in London

Why testing shouldn’t be confined to the lab

Believe it or not, experiments are just as important in marketing as they are in science.

Dice Medical Communications

- PMLiVE

Almirall and Inserm Transfert to develop innovative vitiligo treatments

Vitiligo is a chronic skin condition that affects patients worldwide

- PMLiVE

Recognising HIV Vaccine Awareness Day

HIV Vaccine Awareness Day is on 18 May

- PMLiVE

AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement

RQ BIO has developed a portfolio of early-stage monoclonal antibodies targeting SARS-CoV-2

- PMLiVE

Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data

The potential new oral treatment showed a reduction in lung function decline

- PMLiVE

NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer

The treatment will be available for eligible patients in England with a stage 3 diagnosis

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links